Invasive meningococcal disease has a global impact, affecting various populations across different regions. Outbreaks can occur in closed settings, such as military barracks, schools, and communities, prompting public health responses to control the spread of the bacterium. Global surveillance efforts, including the World Health Organization's (WHO) Global Invasive Bacterial Vaccine-Preventable Diseases (IB-VPD) network, monitor the epidemiology of IMD and inform vaccination strategies. Treatment for invasive meningococcal disease involves the prompt administration of antibiotics, usually third-generation cephalosporins or penicillin, to eradicate the bacterium from the bloodstream. Early recognition and initiation of treatment are crucial for improving outcomes, as the disease can progress rapidly. In addition to antibiotics, close contacts of individuals with invasive meningococcal disease may receive prophylactic antibiotics to prevent secondary cases. Contact tracing and prophylaxis play a key role in controlling outbreaks and preventing further transmission. Despite advances in prevention and treatment, the potential for severe outcomes emphasizes the importance of continued research, vaccination efforts, and global collaboration to address invasive meningococcal disease. Ongoing vigilance and public health initiatives are vital for reducing the burden of this devastating infection and protecting vulnerable populations.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : When acute EBV mimics HIV: A case of false positive p24 antigen and low-level HIV antibody reactivity
Smriti Chaudhary, Imperial College Healthcare NHS Trust, United Kingdom
Title : OnePeru: Peruvian bioinformatics platform to contribute to the fight against antimicrobial resistance
Pool Marcos Carbajal, University of San Martin de Porres, Peru
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain